WMSA
SRPT icon

Weiss Multi-Strategy Advisers’s Sarepta Therapeutics SRPT Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-5,000
Closed -$760K – 693
2019
Q2 		$760K Buy
+5,000
New +$608K 0.02% 399
2018
Q3 		– Sell
-20,000
Closed -$2.64M – 637
2018
Q2 		$2.64M Buy
+20,000
New +$1.89M 0.06% 305
2013
Q4 		– Sell
-20,000
Closed -$945K – 1104
2013
Q3 		$945K Buy
+20,000
New +$770K 0.02% 420

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Weiss Multi-Strategy Advisers's SRPT Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 35,211 shares — an estimated $3.4M sold.

Weiss Multi-Strategy Advisers first reported a position in SRPT in Q2 2013 and held it in 28 quarters. The position peaked at $8.33M in Q2 2018. 414 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

  • Weiss Multi-Strategy Advisers reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 35,211 Sarepta Therapeutics shares in Q1 2024, an estimated $3.4M.
  • Weiss Multi-Strategy Advisers first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 28 quarters.
  • Weiss Multi-Strategy Advisers's Sarepta Therapeutics position peaked at $8.33M in Q2 2018.
  • 414 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.